Bortezomib Is Cytotoxic to the Human Growth Plate and Permanently Impairs Bone Growth in Young Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Eriksson, Emma ^a   Zaman, Farasat ^a   Chrysis, Dionisios ^b   Wehtje, Henrik ^a   Heino, Terhi J ^c   Sävendahl, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BORTEZOMIB; CASPASE 3; MLM 341; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEIN BAX; PROTEIN P53; SOMATOMEDIN C; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DEFECT; BONE GROWTH; BONE REMODELING; CARTILAGE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CYTOTOXICITY; ENZYME DEGRADATION; GROWTH PLATE; GROWTH RETARDATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METATARSAL BONE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; ORGAN CULTURE; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BONE DEVELOPMENT; BORONIC ACIDS; CARTILAGE; CASPASES; CELL LINE; CHONDROCYTES; CHONDROGENESIS; ENZYME ACTIVATION; GROWTH PLATE; HOMEOSTASIS; HUMANS; METATARSAL BONES; MICE; MITOCHONDRIAL MEMBRANES; PROTEASOME INHIBITORS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RATS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

MUS; RATTUS;

EID: 84870575779     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050523     Document Type: Article

References (58)

1. Lowe SW, Lin AW, (2000) Apoptosis in cancer. Carcinogenesis 21: 485-495.
2. Vaux DL, Korsmeyer SJ, (1999) Cell death in development. Cell 96: 245-254.
3. Green DR, (1998) Apoptotic pathways: the roads to ruin. Cell 94: 695-698.
4. Schriock EA, Schell MJ, Carter M, Hustu O, Ochs JJ, (1991) Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol 9: 400-405.
5. Thun-Hohenstein L, Frisch H, Schuster E, (1992) Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma. Horm Res 37: 91-95.
6. Caruso-Nicoletti M, Mancuso M, Spadaro G, Dibenedetto SP, DiCataldo A, et al. (1993) Growth and growth hormone in children during and after therapy for acute lymphoblastic leukaemia. Eur J Pediatr 152: 730-733.
7. Olshan JS, Gubernick J, Packer RJ, D'Angio GJ, Goldwein JW, et al. (1992) The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 70: 2013-2017.
8. Ogilvy-Stuart AL, Shalet SM (1995) Effect of chemotherapy on growth. Acta Paediatr Suppl 411: 52-56.
9. Kirk JA, Raghupathy P, Stevens MM, Cowell CT, Menser MA, et al. (1987) Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukaemia. Lancet 1: 190-193.
10. Adams J, (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360.
11. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, et al. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8: 333-338.
12. Kane RC, Bross PF, Farrell AT, Pazdur R, (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8: 508-513.
13. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, et al. (2007) Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13: 5291-5294.
14. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, et al. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99: 14374-14379.
15. Vousden KH, (2000) p53: death star. Cell 103: 691-694.
16. Martin DA, Elkon KB (2004) Mechanisms of apoptosis. Rheum Dis Clin North Am 30: 441-454, vii.
17. Zaman F, Menendez-Benito V, Eriksson E, Chagin AS, Takigawa M, et al. (2007) Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Cancer Res 67: 10078-10086.
18. Zaman F, Fadeel B, Savendahl L (2008) Proteasome inhibition therapies in childhood cancer. Leukemia 22: 883-884; author reply 884-885.
19. Wu S, De Luca F, (2006) Inhibition of the proteasomal function in chondrocytes down-regulates growth plate chondrogenesis and longitudinal bone growth. Endocrinology 147: 3761-3768.
20. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, et al. (2004) Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 22: 4804-4809.
21. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, et al. (2007) A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 13: 1516-1522.
22. Adams J, Kauffman M, (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 22: 304-311.
23. Spagnoli A, Torello M, Nagalla SR, Horton WA, Pattee P, et al. (2002) Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. J Biol Chem 277: 18860-18867.
24. Spagnoli A, Hwa V, Horton WA, Lunstrum GP, Roberts CT Jr, et al. (2001) Antiproliferative effects of insulin-like growth factor-binding protein-3 in mesenchymal chondrogenic cell line RCJ3.1C5.18. relationship to differentiation stage. J Biol Chem 276: 5533-5540.
25. Levine AJ, (1993) The tumor suppressor genes. Annu Rev Biochem 62: 623-651.
26. Abad V, Meyers JL, Weise M, Gafni RI, Barnes KM, et al. (2002) The role of the resting zone in growth plate chondrogenesis. Endocrinology 143: 1851-1857.
27. Schrier L, Ferns SP, Barnes KM, Emons JA, Newman EI, et al. (2006) Depletion of resting zone chondrocytes during growth plate senescence. J Endocrinol 189: 27-36.
28. Kisselev AF, Goldberg AL, (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739-758.
29. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR, (1998) The p53 network. J Biol Chem 273: 1-4.
30. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, et al. (1998) Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A 95: 14681-14686.
31. Susin SA, Zamzami N, Castedo M, Daugas E, Wang HG, et al. (1997) The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med 186: 25-37.
32. Tang D, Lahti JM, Grenet J, Kidd VJ, (1999) Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism. J Biol Chem 274: 7245-7252.
33. Fearnhead HO, Rodriguez J, Govek EE, Guo W, Kobayashi R, et al. (1998) Oncogene-dependent apoptosis is mediated by caspase-9. Proc Natl Acad Sci U S A 95: 13664-13669.
34. Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, et al. (1998) Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94: 339-352.
35. Yoshida H, Kong YY, Yoshida R, Elia AJ, Hakem A, et al. (1998) Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94: 739-750.
36. Tang D, Lahti JM, Kidd VJ, (2000) Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem 275: 9303-9307.
37. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737.
38. Zaman F, Chrysis D, Huntjens K, Fadeel B, Savendahl L, (2012) Ablation of the pro-apoptotic protein bax protects mice from glucocorticoid-induced bone growth impairment. PLoS One 7: e33168.
39. Muller HL, Klinkhammer-Schalke M, Kuhl J, (1998) Final height and weight of long-term survivors of childhood malignancies. Exp Clin Endocrinol Diabetes 106: 135-139.
40. Arikoski P, Komulainen J, Riikonen P, Jurvelin JS, Voutilainen R, et al. (1999) Reduced bone density at completion of chemotherapy for a malignancy. Arch Dis Child 80: 143-148.
41. Haddy TB, Mosher RB, Reaman GH, (2001) Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist 6: 278-285.
42. Siebler T, Shalet SM, Robson H, (2002) Effects of chemotherapy on bone metabolism and skeletal growth. Horm Res 58 (Suppl 1): 80-85.
43. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, et al. (2003) Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111: 1771-1782.
44. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, et al. (2008) Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118: 491-504.
45. Pennisi A, Li X, Ling W, Khan S, Zangari M, et al. (2009) The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 84: 6-14.
46. Rogol AD, Clark PA, Roemmich JN, (2000) Growth and pubertal development in children and adolescents: effects of diet and physical activity. Am J Clin Nutr 72: 521S-528S.
47. Matyskova R, Maletinska L, Maixnerova J, Pirnik Z, Kiss A, et al. (2008) Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice. Physiol Res 57: 727-734.
48. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, et al. (2006) Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98: 1142-1157.
49. Demetrius L (2005) Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans. EMBO Rep 6 Spec No: S39-44.
50. Chagin AS, Lindberg MK, Andersson N, Moverare S, Gustafsson JA, et al. (2004) Estrogen receptor-beta inhibits skeletal growth and has the capacity to mediate growth plate fusion in female mice. J Bone Miner Res 19: 72-77.
51. Martensson K, Chrysis D, Savendahl L, (2004) Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 19: 1805-1812.
52. Chagin AS, Karimian E, Sundstrom K, Eriksson E, Savendahl L, (2010) Catch-up growth after dexamethasone withdrawal occurs in cultured postnatal rat metatarsal bones. J Endocrinol 204: 21-29.
53. Aubin JE, Heersche JN, Merrilees MJ, Sodek J, (1982) Isolation of bone cell clones with differences in growth, hormone responses, and extracellular matrix production. J Cell Biol 92: 452-461.
54. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, et al. (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46: 673-683.
55. Tivesten A, Moverare-Skrtic S, Chagin A, Venken K, Salmon P, et al. (2004) Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats. J Bone Miner Res 19: 1833-1839.
56. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
57. Chrysis D, Zaman F, Chagin AS, Takigawa M, Savendahl L, (2005) Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3′-kinase signaling pathway. Endocrinology 146: 1391-1397.
58. Frediani P, Nocivelli P, Capilupi B, (1987) [Role of epiphysiodesis in the treatment of leg length inequality]. Chir Organi Mov 72: 221-226.